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Infectious Disease Epidemiology Report
Hepatitis A in Maine, 2012
Background

Signs and symptoms of acute HAV infection include
tiredness, loss of appetite, nausea, abdominal
discomfort, dark urine, clay-colored stool, jaundice
and elevated liver function tests. Acute HAV
infection is classified by a discrete onset of
symptoms, elevated liver enzymes or jaundice, and
positive serology. Symptoms appear within 15 to 50
days of infection with the virus, although children
are less likely to have symptoms. There is no
chronic form of hepatitis A and infection provides
lifelong immunity. There is a vaccine for hepatitis A.

Methods
Acute HAV infections in Maine are reportable
immediately upon recognition or strong suspicion of
disease. Reported cases are investigated by Maine
CDC to determine the exposure, identify close
contacts, and make recommendations for postexposure prophylaxis and prevention.

Results
In 2012, nine cases of acute hepatitis A were
reported in Maine compared to six cases in the
previous year. The rate of acute HAV infection in
Maine was 0.7 cases per 100,000 persons in 2012
(Figure 1).
The majority of the cases (78%) were female in
2012 (Figure 2).
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Figure 2. Count of hepatitis A, Maine
2008-2012 (N=41)
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Hepatitis A is a liver disease caused by hepatitis A
virus (HAV). HAV is spread from person to person
by the fecal-oral route. Poor hand washing by
infected persons increases the risk of transmission.
The virus spreads more easily in areas where
sanitary conditions and personal hygiene practices
are poor. Most infections result from exposure
during international travel or contact with a
household member or sex partner who has
hepatitis A. Casual contact, as in the office or
school setting, does not typically spread the virus.
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Risk factor information was collected for all nine
cases in 2012. Three cases (33%) reported travel
history during the exposure period. One case
identified as a man who has sex with men (MSM).
No risk factor was reported for the remaining five
(56%) cases.
In 2012, hepatitis A cases were reported from five
Maine counties. Five cases (56%) were reported
from Cumberland county and one case each was
reported from Androscoggin, Kennebec, Oxford,
and York counties (Figure 3).
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Figure 3. Hepatitis A cases by county, 2012

Hepatitis A is vaccine-preventable in persons aged
one and older. The vaccine is administered in a 2dose schedule, six months apart. A combined
hepatitis A and hepatitis B (Twinrix) vaccine is also
available for adults age 18 and older. Hepatitis A
vaccine is recommended routinely for children and
for household members and other close personal
contacts of adopted children newly arriving from
countries where HAV infection is endemic.
Infection with HAV can be avoided after exposure
to a confirmed case with timely administration of
hepatitis A vaccine or immune globulin. This is
called post-exposure prophylaxis and is effective if
given within two weeks of exposure.
• For healthy persons aged 12 months-40
years, single-antigen hepatitis A vaccine at
the age-appropriate dose is preferred.
• For persons aged >40 years, IG is
preferred; vaccine can be used if IG cannot
be obtained.
• IG should be used for children aged <12
months, immunocompromised persons,
persons who have had chronic liver disease
diagnosed, and persons for whom vaccine
is contraindicated.

Prevention and Control
Prevention measures for HAV infection include the
following:
• Consider vaccination for all children and
persons at increased risk for HAV infection,
including travelers, MSM, drug users,
persons with occupational risk for infection,
and persons with clotting factor disorders
• Practice good hand washing, especially
before handling or eating food, after toilet
use and after changing diapers
• Dispose of feces in a sanitary manner in
daycare or residential settings
• Avoid sexual practices that may allow fecaloral transmission
• When traveling, do not drink tap water or
use ice and avoid eating uncooked foods in
developing countries where the water may
not be safe and sanitation is poor

Due to the likelihood for false positive results when
diagnostic testing for hepatitis A virus is performed
on asymptomatic persons, CDC recommends that
healthcare providers limit use of IgM anti-HAV
testing to persons with evidence of clinical hepatitis
or to those who have had recent exposure to a
person with an acute HAV infection. Providers
should also not use IgM anti-HAV as a screening
tool for asymptomatic persons or as part of testing
panels for the workup of non-acute liver function
abnormalities.
Acute hepatitis A cases are required to be reported
immediately to Maine CDC at 1-800-821-5821.
Information about hepatitis A is available online at
www.maine.gov/idepi and www.cdc.gov.
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